BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36136268)

  • 1. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
    Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
    Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response.
    Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A
    Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
    Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
    J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
    Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
    J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids.
    Elbadawy M; Hayashi K; Ayame H; Ishihara Y; Abugomaa A; Shibutani M; Hayashi SM; Hazama S; Takenouchi H; Nakajima M; Tsunedomi R; Suzuki N; Nagano H; Shinohara Y; Kaneda M; Yamawaki H; Usui T; Sasaki K
    Biomed Pharmacother; 2021 Oct; 142():112043. PubMed ID: 34411919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
    Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
    Front Oncol; 2022; 12():883437. PubMed ID: 35719949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer.
    Kendzia S; Franke S; Kröhler T; Golob-Schwarzl N; Schweiger C; Toeglhofer AM; Skofler C; Uranitsch S; El-Heliebi A; Fuchs J; Punschart A; Stiegler P; Keil M; Hoffmann J; Henderson D; Lehrach H; Yaspo ML; Reinhard C; Schäfer R; Keilholz U; Regenbrecht C; Schicho R; Fickert P; Lax SF; Erdmann F; Schulz MH; Kiemer AK; Haybaeck J; Kessler SM
    Mol Cancer; 2023 May; 22(1):89. PubMed ID: 37248468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-seq identifies determinants of oxaliplatin sensitivity in colorectal cancer cell lines.
    Li XX; Peng JJ; Liang L; Huang LY; Li DW; Shi DB; Zheng HT; Cai SJ
    Int J Clin Exp Pathol; 2014; 7(7):3763-70. PubMed ID: 25120752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNHG4-mediated PTEN destabilization confers oxaliplatin resistance in colorectal cancer cells by inhibiting ferroptosis.
    Li SQ; Xu WT; Yin YX; Wei HT; Li KZ; Xie MZ; Lv F; Xie LY; Hu BL
    Apoptosis; 2024 Jun; 29(5-6):835-848. PubMed ID: 38573492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
    Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
    ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer.
    Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y
    Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
    Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1/DVL2/Snail axis drives metastasis and chemoresistance of colorectal cancer.
    Yang Y; Jiang H; Li W; Chen L; Zhu W; Xian Y; Han Z; Yin L; Liu Y; Wang Y; Pan K; Zhang K
    Aging (Albany NY); 2020 Dec; 12(23):24424-24440. PubMed ID: 33291076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer.
    Madigan JP; Robey RW; Poprawski JE; Huang H; Clarke CJ; Gottesman MM; Cabot MC; Rosenberg DW
    Exp Cell Res; 2020 Mar; 388(2):111860. PubMed ID: 31972222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIF18b-dependent hypomethylation of PARPBP gene promoter enhances oxaliplatin resistance in colorectal cancer.
    Hong B; Lu R; Lou W; Bao Y; Qiao L; Hu Y; Liu K; Chen J; Bao D; Ye M; Fang Z; Gong C; Zhang X
    Exp Cell Res; 2021 Oct; 407(2):112827. PubMed ID: 34508743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase.
    Zhou Y; Wan G; Spizzo R; Ivan C; Mathur R; Hu X; Ye X; Lu J; Fan F; Xia L; Calin GA; Ellis LM; Lu X
    Mol Oncol; 2014 Feb; 8(1):83-92. PubMed ID: 24145123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin F
    Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
    World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.